No. (%) subjects | |
---|---|
Received latanoprost/timolol FC | 2339 |
Completed 24 months of follow-up | 1317 (56.3) |
Discontinued prior to 24 months | 1022 (43.7) |
Per protocol population | |
Included | 1028 (44.0) |
Excluded | 1311 (66.0) |
Reason(s) for exclusion:* | |
Not treated for ≥18 months | 512 |
No baseline and ≥1 postbaseline measure for IOP ≥18 months apart | 487 |
Additional ocular hypotensive medication during study | 402 |
Ametropy at baseline | 42 |
Full analysis set | |
Included | 1934 (82.7) |
Excluded (no postbaseline IOP measurement) | 405 (17.3) |
Safety population | 2339 (100.0) |